FiercePharma

Allergan Announces FDA Approves Revised Indication for OZURDEX (dexamethasone intravitreal implant) 0.7 mg for the Treatment of Diabetic Macular Edema

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE: AGN) announced today that the U.S. Food and Drug Administration (FDA) has approved OZURDEX® (dexamethasone intravitreal implant) 0.7 mg, a ...
Healio

Intralenticular Ozurdex implant: A rare clinical scenario and timely management

Please provide your email address to receive an email when new articles are posted on . Intravitreal steroids have been widely used in the treatment of various ocular pathologies including macular ...
Medscape

Dexamethasone Implant in Diabetic Macular Edema in Real-life Situations

Purpose To report outcome of eyes with recalcitrant and naive eyes with diabetic macular edema (DME) treated with intravitreal dexamethasone implants (Ozurdex) injection. Methods Retrospective ...
Healio

Ozurdex given at same time as PPV may help stabilize retinal conditions

A sustained-release dexamethasone device implanted during pars plana vitrectomy may be effective in pre-emptively reducing macular edema in patients with various underlying ocular diseases at risk for ...
PharmaTimes

NICE backs Allergan’s Ozurdex, AbbVie’s Humira for uveitis

Cost regulators for the NHS in England and Wales are backing routine use of Allergan’s Ozurdex and AbbVie’s Humira to treat non-infectious posterior uveitis, a form of preventable vision loss. Cost ...
Nature

Monthly OCT monitoring of Ozurdex for macular oedema related to retinal vascular diseases: re-treatment strategy (OCTOME Report 1)

To evaluate the morphological and functional changes following intravitreal Ozurdex (dexamethasone implant) injections in patients with macular oedema (MO) secondary to retinal vascular diseases. The ...
GEN

Allergan Gains FDA Approval for Ozurdex to Treat Noninfectious Posterior Uveitis

Biodegradable implant delivers extended-release corticosteroid dexamethasone via intravitreal injection. FDA cleared Allergan’s Ozurdex® 0.7 mg for noninfectious ocular inflammation, or uveitis, ...
PharmaTimes

NICE recommendation expands patient eligibility for AbbVie’s Ozurdex

Treatment becomes an option for treating visual impairment caused by diabetic macular oedema, regardless of lens status Treatment becomes an option for treating visual impairment caused by diabetic ...
Monthly Prescribing Reference

Ozurdex approved for non-infectious uveitis

OZURDEX (dexamethasone) intravitreal implant by Allergan The FDA has approved Ozurdex (dexamethasone intravitreal implant, from Allergan) for the treatment of non-infectious ocular inflammation, or ...
Nature

Anterior vitreous displacement of the intravitreal dexamethasone implant (Ozurdex)

Ozurdex is a biocompatible implant licensed for the treatment of cystoid macular oedema (CMO) after retinal vein occlusions. We report a case of anterior vitreous displacement of Ozurdex, discussing ...
PR Newswire

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion

Ozurdex ® is the first approved intravitreal injection for RVO in China and is licensed for the treatment of macular edema following BRVO and CRVO. Allergan has accelerated access to this treatment in ...
Medscape

Steroid Implants Best for Improving Vision in Uveitis ME

Dexamethasone implants appear to be the best treatment for persistent or recurrent macular edema that often occurs in patients with uveitis, findings from a new study show. The 12-week, multicenter, ...